Ayorinde Victor Ogundele

Dr. Ayorinde Victor Ogundele

Department of Basic Sciences, Faculty of Medicine, Universidad de La Frontera, Temuco, Araucanía, Chile
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2025 in Carbohydrate Polymer Technologies and Applications
Verified
Journal Article
Open access
OFOluwatoyin Adenike Fabiyi
Oluwatoyin Adenike Fabiyi
Ayorinde Victor OgundeleAyorinde Victor Ogundele
Ayorinde Victor Ogundele
HMHector S. Mella
Hector S. Mella

1 June 2021 in Revista Brasileira de Farmacognosia
Verified
Journal Article
Closed access
PDF file
Ayorinde Victor OgundeleAyorinde Victor Ogundele
Ayorinde Victor Ogundele
AYArchana Yadav
Archana Yadav
ADArchanamoni Moni Das
Archanamoni Moni Das

28 April 2026 in Discover Food
Verified
Journal Article
Open access
OFOluwatoyin Adenike Fabiyi
Oluwatoyin Adenike Fabiyi
Ayorinde Victor OgundeleAyorinde Victor Ogundele
Ayorinde Victor Ogundele
OAOyesolape B. Akinsipo
Oyesolape B. Akinsipo
ABAbosede A. Badeji
Abosede A. Badeji
HSHéctor H. Silva
Héctor H. Silva

25 September 2025 in Antioxidants
Verified
Journal Article
Open access
PDF file
Ayorinde Victor OgundeleAyorinde Victor Ogundele
Ayorinde Victor Ogundele
ADArchanamoni Moni Das
Archanamoni Moni Das
Cristian PazCristian Paz
Cristian Paz
The present study investigates the antioxidant potential of the stem bark of Elaeocarpus floribundus Blume through an integrated approach involving phytochemical isolation, in vitro radical scavenging assays, ADMET-based safety profiling, and molecular docking. Bioassay-guided fractionation of the ethanolic extract into hexane, chloroform, and ethyl acetate fractions revealed the ethyl acetate fraction to possess the highest antioxidant activity, with an IC50 value of 6.19 μg/mL in the DPPH assay, surpassing that of ascorbic acid (IC50 = 9.74 μg/mL). Subsequent isolation and characterization from the ethyl acetate fraction of the stem bark yielded five known compounds from this plant part for the first time, including gallic acid and epigallocatechin gallate. Both compounds showed potent radical scavenging activity in vitro. Among these, gallic acid exhibited superior pharmacokinetic and safety profiles based on in silico ADMET predictions, no Lipinski’s rule violations, and no predicted toxicity. Molecular docking studies showed that gallic acid had high binding affinities for glutathione reductase (GR) and superoxide dismutase (SOD), exceeding those of their reference inhibitors. A docking analysis further revealed stable interactions with catalytically relevant residues, suggesting a stabilizing modulatory effect on redox homeostasis. These findings identify E. floribundus stem bark as a novel source of antioxidant compounds and highlight gallic acid as a promising therapeutic candidate for oxidative stress-related disorders.

31 March 2025 in Molecules
Verified
Journal Article
Open access
PDF file
VMVíctor Manuel Marin Mosi
Víctor Manuel Marin Mosi
CVCECILIA ANDREINA VILLEGAS
CECILIA ANDREINA VILLEGAS
Ayorinde Victor OgundeleAyorinde Victor Ogundele
Ayorinde Victor Ogundele
JCJaime Roberto Cabrera-Pardo
Jaime Roberto Cabrera-Pardo
KSKwesiga Schmidt
Kwesiga Schmidt
VBViviana Burgos
Viviana Burgos
Inflammation contributes to the onset and development of many diseases, including neurodegenerative diseases, caused by the activation of microglia, leading to neurological deterioration. Nuclear factor-κB (NF-κB) is one of the most relevant pathways for identifying anti-inflammatory molecules. In this study, polygodial and isotadeonal, two drimane sesquiterpene dialdehydes, were isolated from Drimys winteri, a medicinal tree of the Mapuche people in Chile. Isotadeonal, or epi-polygodial, was obtained from polygodial by epimerization in basic media (60% yield, Na2CO3, r/t, 24 h). Both sesquiterpenoids were evaluated on the NF-κB pathway, with the result that isotadeonal inhibited the phosphorylation of IκB-α at 10 μM with higher potency by Western blotting. The final inhibition of the pathway was evaluated using a SEAP reporter (secreted alkaline phosphatase) on THP-1 cells. Isotadeonal inhibited SEAP with higher potency than polygodial, quercetin, and CAPE (phenethyl ester of caffeic acid). In silico analysis suggests that the α-aldehyde of isotadeonal adopts a more stable conformation in the active pocket of IκB-α than polygodial.

7 July 2026 in Molecules
Verified
Journal Article
Open access
PDF file
Ayorinde Victor OgundeleAyorinde Victor Ogundele
Ayorinde Victor Ogundele
GNGeetmani Singh Nongthombam
Geetmani Singh Nongthombam
ANAdanna D Nwagu
Adanna D Nwagu
HSHéctor Silva
Héctor Silva
OFOluwatoyin Adenike Fabiyi
Oluwatoyin Adenike Fabiyi
Animal venoms represent an extraordinary, yet largely untapped, biochemical reservoir for oncological drug discovery. This review provides a comprehensive analysis of venom-derived enzyme inhibitors as emerging anticancer agents, emphasizing their chemical diversity, structure–activity relationships (SAR), molecular targets, and mechanistic pathways. Venom-derived peptides and proteins exhibit exceptional binding affinity and structural rigidity, characteristics frequently enforced by conserved disulfide networks. This specific architecture allows them to selectively modulate critical cancer-associated enzymes, including matrix metalloproteinases, phospholipases A2, serine proteases, and kinases. Inhibiting these highly specific targets successfully disrupts tumour angiogenesis, extracellular matrix remodelling, and metastatic dissemination, while simultaneously inducing apoptosis through unique pathways such as reactive oxygen species generation. Modern computational approaches, encompassing deep learning algorithms, molecular docking, and molecular dynamics simulations, are substantially accelerating and transforming the discovery pipeline by rapidly mapping intricate peptide–receptor interactions and guiding rational drug design. Translating these potent molecules into clinical therapeutics remains heavily challenged by pharmacokinetic instability, rapid proteolytic degradation, and systemic toxicity. The integration of computationally optimized scaffolds with advanced targeted delivery platforms, such as nanocarriers and liposomal encapsulation, offers a highly viable strategy to overcome these barriers, ultimately paving the way for next-generation, venom-inspired cancer therapies.